KIT and melanoma: They also demonstrated that Nilotinib significantly decreased STAT3 phosphorylation in melanoma cell lines and inhibited cell proliferation as efficiently as specific STAT3 inhibitors [11], suggesting that the interaction of c-Kit with STAT3 should be considered when assessing responses to c-Kit inhibitors in cancer models.